Intravitreal bevacizumab appears to be safe in treatment of retinopathy of prematurity

The use of intravitreal bevacizumab appears to be safe in preterm infants for treatment of retinopathy of prematurity, according to a long-term multicenter study.

NIH research points to microglia as potential therapeutic target in Retinitis Pigmentosa

Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection. But a new study by researchers at the National Eye Institute (NEI) shows that they also accelerate damage wrought by blinding eye disorders, such as retinitis pigmentosa.

A Blind Architect leads his Berkeley Students to equitable, barrier-eliminating design solutions

Oh, that we could see as clearly as blind architect Chris Downey. Leading his UC Berkeley seminar students to equitable, barrier-eliminating design solutions or consulting on a 170,000-square-foot blind rehab center at the Veterans Affairs center in Palo Alto or filling the stroke seat on his East Bay Rowing Club team, the 52-year-old Piedmont architect and teacher says he lacks sight, but is not without vision.

Sunglasses should be used from an early age to prevent eye problems in the future

This summer, when your kids pack for summer camp, make sunglasses a top priority in the supply list.

Results in Ocuvia Diabetic Macular Edema Study show promise

ReVIEW study outcomes so far indicated that Ocuvia, a investigational topical ophthalmic formulation to treat the underlying defects in mitochondria in retinal diseases, shows promise in patients with diabetic macular edema.

Stem cells for treatment of diabetic retinopathy - positive results in the lab

University of Virginia School of Medicine researchers have taken a significant step forward in their efforts to use stem cells to block vision loss caused by diabetic retinopathy, a condition that affects millions of people with diabetes. The researchers have evaluated the best potential sources for adult stem cells to be used for that purpose, determining that cells taken from donors who do not suffer diabetes likely will be more effective than cells taken from patients' own bodies.

Patients using Argus II report improvement in visual function and quality of life

The three-year clinical trial results of the retinal implant, popularly known as the "bionic eye," have proven the long-term efficacy, safety and reliability of the device that restores vision in those blinded by Retinitis Pigmentosa (RP), a rare, degenerative eye disease. The findings show that the Argus II significantly improves visual function and quality of life for people blinded by RP.